Posts

Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production

on

Astellas five‑year plan targets record sales and deep cost cuts through 2030

on

ZyDoc to Showcase New Approach to AI Innovation in Healthcare at SUNY AI Symposium with No Cost to Providers

on

FDA Reduces Regulatory Red Tape for Biosimilars

on

IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path

on

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

on

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

on

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

on

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

on

Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies

on

Recent Developments in Building Measurable Patient Support Programs (2025)

on

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

on

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

on

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

on

Schrödinger Lays Off 60 Staffers Amid Economic Uncertainty

on

Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase

on

BMS to close Illinois site as part of cell therapy manufacturing consolidation

on

Moderna expands effort to rein in costs in an uncertain environment

on

Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027

on

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

on